297 related articles for article (PubMed ID: 34067027)
1. Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity.
Darakjian L; Deodhar M; Turgeon J; Michaud V
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34067027
[TBL] [Abstract][Full Text] [Related]
2. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
Shah RR; Smith RL
Drug Metab Dispos; 2015 Mar; 43(3):400-10. PubMed ID: 25519488
[TBL] [Abstract][Full Text] [Related]
3. Modulation of CYP450 Activities in Patients With Type 2 Diabetes.
Gravel S; Chiasson JL; Turgeon J; Grangeon A; Michaud V
Clin Pharmacol Ther; 2019 Dec; 106(6):1280-1289. PubMed ID: 31099895
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case-control pharmacokinetic study.
Gravel S; Chiasson JL; Dallaire S; Turgeon J; Michaud V
BMJ Open; 2018 Feb; 8(2):e020922. PubMed ID: 29439084
[TBL] [Abstract][Full Text] [Related]
5. MiR-155 and other microRNAs downregulate drug metabolizing cytochromes P450 in inflammation.
Kugler N; Klein K; Zanger UM
Biochem Pharmacol; 2020 Jan; 171():113725. PubMed ID: 31758923
[TBL] [Abstract][Full Text] [Related]
6. Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review.
Klomp SD; Manson ML; Guchelaar HJ; Swen JJ
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32906709
[TBL] [Abstract][Full Text] [Related]
7. Role of cytochrome P450-derived, polyunsaturated fatty acid mediators in diabetes and the metabolic syndrome.
Dos Santos LRB; Fleming I
Prostaglandins Other Lipid Mediat; 2020 Jun; 148():106407. PubMed ID: 31899373
[TBL] [Abstract][Full Text] [Related]
8. Hepatic cytochrome P450 regulation in disease states.
Cheng PY; Morgan ET
Curr Drug Metab; 2001 Jun; 2(2):165-83. PubMed ID: 11469724
[TBL] [Abstract][Full Text] [Related]
9. Elevated Serum TNF-
Alzamil H
J Obes; 2020; 2020():5076858. PubMed ID: 32089876
[TBL] [Abstract][Full Text] [Related]
10. The Evaluation of
Giorgetti A; Amurri S; Fazio G; Bini C; Anniballi L; Pirani F; Pelletti G; Pelotti S
Metabolites; 2023 May; 13(5):. PubMed ID: 37233702
[TBL] [Abstract][Full Text] [Related]
11. Time-dependent effects of Klebsiella pneumoniae endotoxin on hepatic drug-metabolizing enzyme activity in rats.
Nadai M; Sekido T; Matsuda I; Li W; Kitaichi K; Itoh A; Nabeshima T; Hasegawa T
J Pharm Pharmacol; 1998 Aug; 50(8):871-9. PubMed ID: 9751451
[TBL] [Abstract][Full Text] [Related]
12. HepaRG cells as human-relevant in vitro model to study the effects of inflammatory stimuli on cytochrome P450 isoenzymes.
Rubin K; Janefeldt A; Andersson L; Berke Z; Grime K; Andersson TB
Drug Metab Dispos; 2015 Jan; 43(1):119-25. PubMed ID: 25371393
[TBL] [Abstract][Full Text] [Related]
13. A Pilot Study towards the Impact of Type 2 Diabetes on the Expression and Activities of Drug Metabolizing Enzymes and Transporters in Human Duodenum.
Gravel S; Panzini B; Belanger F; Turgeon J; Michaud V
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269743
[TBL] [Abstract][Full Text] [Related]
14. Quantifying the Impact of Phenoconversion on Medications With Actionable Pharmacogenomic Guideline Recommendations in an Acute Aged Persons Mental Health Setting.
Mostafa S; Polasek TM; Sheffield LJ; Huppert D; Kirkpatrick CMJ
Front Psychiatry; 2021; 12():724170. PubMed ID: 34489765
[No Abstract] [Full Text] [Related]
15. Imbalanced low-grade inflammation and endothelial activation in patients with type 2 diabetes mellitus and erectile dysfunction.
Araña Rosaínz Mde J; Ojeda MO; Acosta JR; Elías-Calles LC; González NO; Herrera OT; García Álvarez CT; Rodríguez EM; Báez ME; Seijas EÁ; Valdés RF
J Sex Med; 2011 Jul; 8(7):2017-30. PubMed ID: 21554550
[TBL] [Abstract][Full Text] [Related]
16. Effects of enzyme induction therapy on glucose and drug metabolism in obese mice model of non-insulin dependent diabetes mellitus.
Karvonen I; Stengård JH; Huupponen R; Stenbäck FG; Sotaniemi EA
Diabetes Res; 1989 Feb; 10(2):85-92. PubMed ID: 2501061
[TBL] [Abstract][Full Text] [Related]
17. Cytochrome P-450-dependent mixed-function oxidase and glutathione S-transferase activities in spontaneous obesity-diabetes.
Barnett CR; Abbott RA; Bailey CJ; Flatt PR; Ioannides C
Biochem Pharmacol; 1992 Apr; 43(8):1868-71. PubMed ID: 1575780
[TBL] [Abstract][Full Text] [Related]
18. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
19. Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure.
Frye RF; Schneider VM; Frye CS; Feldman AM
J Card Fail; 2002 Oct; 8(5):315-9. PubMed ID: 12411982
[TBL] [Abstract][Full Text] [Related]
20. Factors involved in phenoconversion of CYP3A using 4β-hydroxycholesterol in stable kidney transplant recipients.
Suzuki Y; Muraya N; Fujioka T; Sato F; Tanaka R; Matsumoto K; Sato Y; Ohno K; Mimata H; Kishino S; Itoh H
Pharmacol Rep; 2019 Apr; 71(2):276-281. PubMed ID: 30826567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
